Navigation Links
Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
Date:4/16/2008

INS-19 Receives Regulatory Clearance

RICHMOND, Va., April 16 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it has received approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) to initiate the Company's first clinical study for a follow-on biologic (FOB) product candidate. Insmed's INS-19, which is a recombinant form of human G-CSF, is a follow-on biologic of the FDA-approved product Neupogen(R), which had U.S. sales of approximately $0.9 billion in 2007.

Pre-clinical studies demonstrate that INS-19 and FDA-approved Neupogen(R) are comparable in both their pharmacological and toxicological profile. Detailed analytical characterisation also demonstrates that the products have a high degree of similarity. Data from these initial evaluations have been used, in part, to support the Phase I study, which will be initiated immediately. The Phase I study will be conducted in the UK and will compare the safety and establish the bioequivalence of INS-19 to Neupogen(R). Results from the trial are expected in the second half of 2008, and are planned to be used as part of a submission to the FDA to establish a protocol with the agency for a Phase III trial in the U.S.

"By utilizing Insmed's unique protein drug development capabilities and technical expertise, the Company has been able to advance a follow-on biologic product candidate from project initiation to human testing in less than one year, a significant achievement," said Geoffrey Allan, CEO of Insmed. "We intend to utilize the data generated from the Phase I trial, in combination with the positive preclinical results previously garnered, as the basis for discussions with the FDA in an effort to establish a Phase III development path for INS-19."

The initiation of this follow-on biologic trial is the first of two planned for 2008 as part of Insme
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
2. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
3. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
4. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
5. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
6. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Metabolex Initiates Phase 1 Trial of MBX-2982
11. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... expected to begin trading on The NASDAQ Stock Market ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... , June 14 Upsher-Smith Laboratories, Inc. today ... for USL255 (extended-release topiramate), an internally developed program for the ... technology.  USL255 is designed to provide convenient once-daily dosing and ... topiramate options. , , ...
... /PRNewswire/ -- MedShape Solutions, Inc. was recently ... for their MORPHIX™ Suture Anchor at the recent Medical ... of jurors awarded the MORPHIX™ Anchor the Gold Award ... proprietary shape memory polymer, PEEK Altera™.  Previous winners of ...
Cached Medicine Technology:Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy 2Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy 3MedShape Solutions, Inc. Receives Industry Honors and Awards 2
(Date:8/23/2014)... 23, 2014 Professional kitchen employees, prospective ... aid in preparing for Food Safety Certification exams thanks ... by Dynamic Path. , Dynamic Path announced the release ... more than 200 review questions for culinary industry students ... to cover requirements of the ServSafe® Food Safety Certification, ...
(Date:8/23/2014)... TX (PRWEB) August 23, 2014 Youth ... of Texas. It’s no different in Houston, TX. Substance ... are falling victim to drug and alcohol dependency in ... are looking to beat substance abuse, but don’t know ... juvenile treatment facility can be a challenge because most ...
(Date:8/22/2014)... Search Engine Optimization is needed to bring a ... and get more audience and sales. Top 10 ... hosting suppliers and announced that HostGator.com ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... hosting suppliers for webmasters from the USA, UK, ... Linux hosting (including VPS and cloud hosting). , ...
(Date:8/22/2014)... 23, 2014 Recently, Skmen.com, an experienced ... of 2014 bohemian dresses in its online store. Moreover, ... prices, up to 28% off. All the international clients ... August 31, 2014. , The company’s professional online ... to show worldwide customers more the latest information about ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
Breaking Medicine News(10 mins):Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Cheap Bohemian Dresses Unveiled by Experienced Supplier Skmen.com 2Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2
... today (Oct. 31) announced that it is partnering with ... Medical School to administer a transformative $7.2 million project ... in Liberia, an African nation with which IU has ... the Center for Excellence in Health and Life Sciences ...
... to tackle hospital-acquired infections, such as C. difficile ... infections following specific surgical procedures. That is the key ... of the urology journal BJUI . UK ... a standard surgical procedure to diagnose prostate cancer developed ...
... Certain factors unique to professional sports can increase the risk ... staff, a new report suggests. Norovirus is the most ... and causes 21 million cases of illness in the United ... 31 online edition of the journal Clinical Infectious Diseases ...
... a 2010 outbreak involving several NBA teams, the ... a professional sports association. Published in Clinical ... ), the study highlights unique circumstances for spreading ... on and off the court. Norovirus ...
... 2011)In a technical tour de force, scientists at Fox ... of 178 candidate drugs capable of blocking the activity ... critical for cancer and other diseases. Additionally, a free ... to the research community. This unique library represents an ...
... , SUNDAY, Oct. 30 (HealthDay News) --,A physically active ... a new study. Glaucoma, a leading cause of blindness, ... damages the optic nerve. In this study, researchers looked ... 5,650 men and women aged 48 to 90 in Britain. ...
Cached Medicine News:Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 2Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 3Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 4Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 5Health News:Drugs used to tackle hospital-acquired infections can increase post-op complications 2Health News:Stomach Bug Easily Passed Among Pro Sports Teams: Report 2Health News:NBA players not immune to serious illness from norovirus 2Health News:First-of-its-kind study creates new tool for targeted cancer drug development 2Health News:First-of-its-kind study creates new tool for targeted cancer drug development 3Health News:Glaucoma Experts Eye Benefits of Exercise 2
ENDO STITCH™ Single Use Loading Units....
... single use suturing device has application ... of interrupted or running stitches in ... use suturing device is available in ... with the choice of 4 suture ...
... Suture Assistant is a sterile, single-patient-use instrument ... and in placing a suture and a ... button to tie a secure intracorporeal knot., ... the ENDOPATH 5mm trocars or larger trocars ...
... 42" long suture inserted into a plastic tube. ... and scored on the other. The suture protrudes ... ST-3 needle. The opposite end of the suture ... plastic tube. The scored end acts as the ...
Medicine Products: